Currently Viewing:
American Psychiatric Association 2019 Annual Meeting
Currently Reading
Dr David Kingdon on the Principles Underlying the Use of CBT in Psychosis
May 19, 2019
Studies Reveal Loneliness, Trauma Effects Among Minority Urban Women
May 20, 2019
Hochschild Gives Psychiatrists a View of Bridging the Political Chasm
May 20, 2019
Dr Lori Raney Outlines the Advantages and Limitations of Treating Mental Health Disorders in Primary Care Settings
May 20, 2019
Dr Steven Adelsheim Discusses Changing Stigmas Around Mental Illness in Young People
May 20, 2019
Dr Jacob Ballon: Coordinated Teams, Collaboration Are Key to Supporting People With Psychosis
May 21, 2019
TRANSFORM-2 Results on Esketamine Published, Along With Caveats
May 21, 2019
Poll Finds Most Workers Can Get Mental Health Care, but a Third Worry About Seeking It
May 21, 2019
Adam Simmons on Patient Preferences When Taking Antipsychotic Medications
May 21, 2019
Alkermes' Novel Schizophrenia Drug Shows Less Weight Gain, Addressing Top Patient Complaint
May 21, 2019
Where Culture and Science Collide: How Ethnic, Social Factors Affect Response to Psychotropic Drugs
May 22, 2019
Dr Godfrey Pearlson on the Merits of Using Biological Measures to Classify Psychiatric Diseases
May 23, 2019
Dr Isaac Galatzer-Levy Explains How a Predictive Algorithm Uses Machine Learning to Predict PTSD Risk
May 23, 2019
Dr King Davis Explains the Privacy Dangers of Digitizing Archives, Including Psychiatric Records
May 24, 2019
Dr David Kingdon Discusses How CBT Techniques Tailored to Psychosis Can Help Patients Feel Understood
May 30, 2019
Dr Jonathan Avery Discusses Causes and Consequences of Concurrent Mental Illness and Substance Use Disorders
May 31, 2019
Adam Simmons Outlines Efficacy of ALKS 3831 Across Subgroups of Patients With Schizophrenia
June 11, 2019
Dr Lori Raney Defines Integrated, Collaborative Care for Behavioral Health
June 13, 2019
Dr David Kingdon Describes How CBT Can Fit Into a Psychosis Treatment Plan
June 17, 2019
Dr Steven Adelsheim Discusses the Importance of Early Diagnosis for Young People With Psychosis
June 20, 2019
Dr Isaac Galatzer-Levy Explains the Importance of Accurately Predicting PTSD After a Traumatic Event
June 22, 2019
Dr Jonathan Avery Explains How Substance Use Affects the Care of Patients With Mental Illness
June 23, 2019
Dr David Kingdon on the Factors Predicting CBT Success in Psychosis
June 25, 2019
Adam Simmons Explains the Importance of Finding New Treatment Options for Schizophrenia
June 29, 2019

Adam Simmons Explains the Short- and Long-term Value of ALKS 3831 to Payers and Patients

Adam Simmons, director of clinical program management, Alkermes, explains that an investigational antipsychotic drug, ALKS 3831, provides the efficacy of olanzapine without the associated weight gain can provide benefits in the short and long term to payers and patients. Simmons spoke about data presented at the 175th Annual Meeting of the American Psychiatric Association in San Francisco, California.


Adam Simmons, director of clinical program management, Alkermes, explains that an investigational antipsychotic drug, ALKS 3831, that provides the efficacy of olanzapine without the associated weight gain can provide benefits in the short and long term to payers and patients.

Transcript

What’s the potential value of ALKS 3831 to payers and patients?

What we’re doing here in presenting the data at APA is specifically getting this out to physicians, talking about it with patients, and in the upcoming months we’ll be able to get some more information specifically about what the value is to payers. I can say in terms of potential value that there’s probably 2 areas that this medication’s going to be valuable, at least to patients and providers.

One, in the short term, we know that for people with schizophrenia it’s a lifelong disease and that in order for them to do well with their maintenance medications they need to stay on their medications, so that if we’ve been able to take a medication that’s already effective and that people sometimes come off of it because of weight gain, if they’re more likely to stay on their medications they’re more likely to stay out of the hospitals and all of the other bad things that happen when patients stop taking their medications, increased risk for suicide, et cetera.

The other long-term value, of course, is that we know that a lot of people stay on olanzapine despite the weight gain, and that longtime, lifelong exposure of higher weight gain is likely to cause a lot of other comorbidities: cardiovascular disease, type 2 diabetes, et cetera. So we think that there’s a value both from the short term, in terms of people staying on their medication and doing well as a maintenance therapy, as well as long term, in not developing comorbidities.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up